Display options
Cite
Meinertz T, Kasper W, Schumacher M, et al. The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction. Am J Cardiol. 1988;62(7):347-51doi: 10.1016/0002-9149(88)90956-3.
Meinertz, T., Kasper, W., Schumacher, M., & Just, H. (1988). The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction. The American journal of cardiology, 62(7), 347-51. https://doi.org/10.1016/0002-9149(88)90956-3
Meinertz, T, et al. "The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction." The American journal of cardiology vol. 62,7 (1988): 347-51. doi: https://doi.org/10.1016/0002-9149(88)90956-3
Meinertz T, Kasper W, Schumacher M, Just H. The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction. Am J Cardiol. 1988 Sep 01;62(7):347-51. doi: 10.1016/0002-9149(88)90956-3. PMID: 3046283.
Copy Download .nbib Format: NLM
Share it on
Full text links
Elsevier Science

Am J Cardiol. 1988 Sep 01;62(7):347-51. doi: 10.1016/0002-9149(88)90956-3.

The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction.

The American journal of cardiology

T Meinertz, W Kasper, M Schumacher, H Just

Affiliations

  1. Medical Clinic III, University of Freiburg, Federal Republic of Germany.

PMID: 3046283 DOI: 10.1016/0002-9149(88)90956-3

Abstract

A multicenter randomized trial of anisoylated plasminogen streptokinase activator complex (APSAC) versus heparin in patients with acute myocardial infarction of less than 4 hours' duration was undertaken in 19 hospitals. Of the 313 patients, 151 received heparin and 162 APSAC (30 U as intravenous injection). Within 28 days of hospital stay, 19 deaths (12.6%) occurred in the heparin group and 9 deaths (5.6%) in the APSAC group (p = 0.032). After 24 hours, patients in the APSAC group had a significantly lower incidence of cardiogenic shock (3.2 vs 9.5%, p = 0.031), asystole (3.8 vs 10.8%, p = 0.015) and need for resuscitation (5.1 vs 11.5%, p = 0.039). There was no difference in global and infarct-related ejection fraction between the 2 groups. Thus, APSAC favorably influences prognosis and clinical course in hospital.

Cited by

Substances

MeSH terms

Publication Types

LinkOut - more resources